Andreas Burchert

20PUBLICATIONS
120CO-AUTHORS
Molecular targetsInnate immunityHaematologyCancer therapy (excl. chemotherapy and radiation therapy)Medical mycology
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (20)

|Jun 18, 2026
Comprehensive molecular characterization of treatment-free remission and molecular relapse in chronic myeloid leukemia patients: the EURO-SKI Biomarker Study.

|May 26, 2026
Response to: Potential impact of NK-cell education on interferon efficacy in the ENDURE trial.

|Apr 08, 2026
Haploidentical transplantation with post-transplant cyclophosphamide is not inferior to 9/10-MUD transplantation with ATG in patients with myeloid malignancies.

Andrea Gantner, Svenja Labuhn, Daniel Fürst

|Jan 12, 2026
Randomized phase 3 trial of Ropeginterferon alfa-2b versus surveillance after tyrosine kinase inhibitor discontinuation in chronic myeloid leukemia (ENDURE/CML-IX).

Andreas Burchert, Franck E Nicolini, Philipp le Coutre

|Dec 19, 2025
Treatment expectations and goals among patients with chronic myeloid leukemia in Germany: a patient-centered perspective.

Philipp Ernst, Cera Lohse, Michael Lauseker

|Oct 28, 2025
Differential prognostic impact of myelodysplasia-related gene mutations in a European cohort of 4978 intensively treated AML patients.

Marius Bill, Jan-Niklas Eckardt, Konstanze Döhner

Pageof 4

Frequent Collaborators

10 joint publications

Stefan W Krause

8 joint publications

Tim H Brümmendorf

7 joint publications

Johannes Schetelig

6 joint publications

Sebastian Stasik